Accumulating clinical results have indicated that Annexin A2 (ANXA2) promotes tumour metastasis by inducing the conversion of plasminogen to plasmin (14), alteration of molecular tyrosine 23 phosphorylation (15,16), interaction with HAb18G/CD147 (17), activation of matrix metalloproteinases (MMPs) and degradation of extracellular matrix (ECM) components (18). Here, ANXA2 is linked to neoplasm.